Physician profile
Mary Bogner
NPI 1639559867
$6,566.37
in general payments reported to CMS, 2019-2025
31 companies · $999 in 2025
The $999 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,704 · 2022: $1,630 · 2023: $1,292 · 2024: $942 · 2025: $999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,233.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,018.75 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $946.14 | 2021-2025 | |
| Abbott Laboratories | $817.58 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $774.41 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $577.24 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $433.66 | 2021-2025 | |
| Amgen INC. | $294.94 | 2021-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $273.38 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $209.08 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $137.25 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $132.28 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.94 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $114.20 | 2021-2023 | |
| Xeris Pharmaceuticals, INC. | $99.88 | 2022-2024 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $97.10 | 2021-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $86.22 | 2022-2024 | Prolastin-C Liquid |
| Biohaven Pharmaceuticals, INC. | $65.25 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $51.86 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $45.70 | 2021-2023 | Ajovy |
| Amarin Pharma, INC. | $37.12 | 2021 | |
| Esperion Therapeutics, INC. | $35.34 | 2021 | |
| Astellas Pharma US INC | $34.03 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.50 | 2021-2022 | |
| Dynavax Technologies Corporation | $22.23 | 2022-2023 | Heplisav-B |
| Inspire Medical Systems, INC. | $18.67 | 2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $18.26 | 2022 | |
| Heartflow, INC. | $16.96 | 2025 | |
| Edwards Lifesciences Corporation | $16.09 | 2021 | |
| Pulmonx Corporation | $15.50 | 2024 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.49 | 2023 | Xifaxan |
| Amryt Pharma Holdings LTD | $15.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Bogner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.